A single-cell multi-omic atlas of neuroendocrine carcinoma of the cervix identified DLL3 as a driver linked to immune evasion and validated DLL3-targeted therapy in patient-derived organoid models. The work ties tumor heterogeneity at single-cell resolution to a tractable therapeutic lever, aiming to move beyond broad neuroendocrine markers toward a mechanism-specific target. Because DLL3 has been a known focus in some neuroendocrine settings, this dataset-driven reinforcement in cervical disease could accelerate translation of DLL3-directed approaches into more tailored clinical development.